sugammadex (Bridion)

following a resubmission:

sugammadex (Bridion®) is accepted for restricted use within NHS Scotland for the routine reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults and rocuronium in children and adolescents.

Indication under review: Reversal of neuromuscular blockade induced by rocuronium or vecuronium.  For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents.  This resubmission is for the part of the indication relating to routine reversal of neuromuscular blockade.

SMC restriction: only for use in the routine reversal setting in high-risk patients (e.g. morbid obesity, significant respiratory disease or reduced respiratory reserve, significant coronary disease, major abdominal/chest surgery) or where prompt reversal of neuromuscular block is required. 

Sugammadex, when administered after rocuronium or vecuronium, has been shown to provide more rapid reversal of moderate and profound neuromuscular blockade than an anti-cholinesterase comparator.

Sugammadex is significantly more expensive than conventional treatments used to reverse neuromuscular blockade.